Cargando…

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma

Active specific immunotherapy of cancer requires an efficient induction and effector phase. The induction covers potent activation of anti-tumor response, whereas effector breaks the immunosuppression. We report efficacy of therapeutic melanoma vaccine (AGI-101H) used alone in advanced disease as a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacek, Mackiewicz, Aldona, Karczewska-Dzionk, Maria, Laciak, Malgorzata, Kapcinska, Maciej, Wiznerowicz, Tomasz, Burzykowski, Zakowska, Monika, Stefan, Rose-John, Andrzej, Mackiewicz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616404/ https://www.ncbi.nlm.nih.gov/pubmed/26020391 http://dx.doi.org/10.1097/MD.0000000000000853

Ejemplares similares

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma: Erratum
Publicado: (2015)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
por: Kwiatkowska-Borowczyk, Eliza, et al.
Publicado: (2018)

What is new in the treatment of advanced melanoma? State of the art
por: Mackiewicz, Jacek
Publicado: (2012)

Tomotherapy – a different way of dose delivery in radiotherapy
por: Piotrowski, Tomasz, et al.
Publicado: (2012)

Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2017)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model
por: Mackiewicz, Jacek, et al.
Publicado: (2015)

Designer Cytokine Hyper Interleukin 11 (H11) is a Megakaryopoietic Factor
por: Dams-Kozlowska, Hanna, et al.
Publicado: (2013)

A designer hyper interleukin 11 (H11) is a biologically active cytokine
por: Dams-Kozlowska, Hanna, et al.
Publicado: (2012)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
por: Przybyla, Anna, et al.
Publicado: (2021)

Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report
por: Yamaguchi, Kyoko, et al.
Publicado: (2021)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

Characteristics and prognosis of primary malignant melanoma of the esophagus
por: Chen, Hengchi, et al.
Publicado: (2020)

Prognostic factors for postoperative survival in melanoma patients with bone metastasis
por: Wang, Yucheng, et al.
Publicado: (2021)

Analysis of sequence variants in the 3'UTR of CDKN2A gene in melanoma patients
por: Przybyła, Anna, et al.
Publicado: (2015)

Primary cerebral malignant melanoma: A case report with literature review
por: Tang, Kai, et al.
Publicado: (2017)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2020)

Novel oxidative stress-related prognostic biomarkers for melanoma associated with tumor metastasis
por: Wu, Xianpei, et al.
Publicado: (2021)

Prognostic significance of platelet lymphocyte ratio in patients with melanoma: A meta-analysis
por: Wang, Enwen, et al.
Publicado: (2021)

Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed Mice
por: Dams-Kozlowska, Hanna, et al.
Publicado: (2016)

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines
por: Guglas, Kacper, et al.
Publicado: (2018)

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas
por: Kolenda, Tomasz, et al.
Publicado: (2019)

LATS1 Is a Mediator of Melanogenesis in Response to Oxidative Stress and Regulator of Melanoma Growth
por: Kazimierczak, Urszula, et al.
Publicado: (2021)

GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
por: Patel, Sapna P., et al.
Publicado: (2016)

The clinical features, treatment, and prognosis of primary mediastinal malignant melanoma: A case report
por: Li, ZiHai, et al.
Publicado: (2017)

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report
por: Abdou, Yara, et al.
Publicado: (2019)

Construction of autophagy prognostic signature and analysis of prospective molecular mechanisms in skin cutaneous melanoma patients
por: Liao, Shian, et al.
Publicado: (2021)

Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma
por: Slupski, Maciej W, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_luim7re4ok9di0b7tigdlfcm69